Trials / Completed
CompletedNCT02644616
The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Shanghai Chest Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators research the early improvement of fluid retention and mid-term prognosis through the administration of tolvaptan for the patient with tricuspid regurgitation and right heart failure after left heart valves replacement.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tolvaptan+torasemide | tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv |
| DRUG | placebo+torasemide | placebo 15mg/d po(10 days) +torasemide 20mg/d iv |
Timeline
- Start date
- 2014-11-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2016-01-01
- Last updated
- 2016-12-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02644616. Inclusion in this directory is not an endorsement.